GlassScriptPhysician profile
Jessica Sickler Schmidt
NPI 1205181005
$3,540.58
in general payments reported to CMS, 2019-2025
19 companies · $1,136 in 2025
The $1,136 reported for 2025 was more than what 83% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $611 · 2022: $548 · 2023: $719 · 2024: $527 · 2025: $1,136.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,382.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,381.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,297.26 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $385.66 | 2022-2025 | Caplyta |
| Alkermes, INC. | $289.26 | 2022-2025 | Aristada, Lybalvi, Vivitrol |
| Otsuka America Pharmaceutical, INC. | $203.93 | 2023-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $180.95 | 2021-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $166.41 | 2023-2025 | Spravato |
| Lundbeck LLC | $161.65 | 2022-2025 | Rexulti, Abilify Maintena |
| Axsome Therapeutics, INC. | $149.27 | 2023-2025 | Auvelity |
| Bausch Health US, LLC | $144.89 | 2022-2024 | Aplenzin |
| Teva Pharmaceuticals USA, INC. | $119.18 | 2021-2025 | Uzedy, Austedo Xr |
| Gilead Sciences, INC. | $99.86 | 2021 | |
| Indivior INC. | $82.71 | 2024-2025 | Sublocade |
| Vanda Pharmaceuticals INC. | $65.23 | 2022-2023 | Fanapt, Hetlioz |
| Supernus Pharmaceuticals, INC. | $63.81 | 2023-2024 | Qelbree, Qelbree |
| Almatica Pharma LLC | $34.66 | 2025 | Loreev Xr |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $29.74 | 2021-2022 | |
| Biogen, INC. | $28.42 | 2025 | Zurzuvae |
| Corium, LLC | $20.74 | 2024 | Azstarys |
| Braeburn INC. | $16.95 | 2024 | Brixadi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessica Schmidt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.